Background: We assessed the effect of once-weekly semaglutide and once-daily liraglutide
on kidney outcomes in type 2 diabetes. Methods: Pooled (n= 12 637) and by-trial data from …

Aims To investigate whether effects on chronic kidney disease risk factors could explain the
apparent reduction in kidney outcomes (composite of macroalbuminuria, doubling of serum …

Associations between body mass index (BMI) and the cardiovascular (CV) and kidney
efficacy of glucagon‐like peptide‐1 receptor agonists (GLP‐1 RAs) in patients with type 2 …

Glucagon-like peptide-1 receptor agonists reduce albuminuria and may stabilize the
estimated glomerular filtration rate (eGFR) in people with type 2 diabetes (T2D). In this post …

Background Chronic kidney disease (CKD) is a common complication of type 2 diabetes
(T2D). Glucagon-like peptide-1 receptor agonists (GLP-1RAs) improve glycaemic control …

Hyperglycaemia contributes to the onset and progression of diabetic kidney disease (DKD).
Observational studies have not consistently demonstrated a glucose threshold, in terms of …

Aims In a short-term study including 31 patients with type 2 diabetes, glucagon-like peptide
1 receptor agonist (GLP-1 RA) treatment was associated with a significant reversible decline …

Background In a randomized, controlled trial that compared liraglutide, a glucagon-like
peptide 1 analogue, with placebo in patients with type 2 diabetes and high cardiovascular …

Background: LEADER trial (Liraglutide Effect and Action in Diabetes: Evaluation of CV
Outcome Results) results demonstrated cardiovascular benefits for patients with type 2 …

Background Patients with type 2 diabetes and chronic kidney disease are at high risk for
kidney failure, cardiovascular events, and death. Whether treatment with semaglutide would …